Complete clearance · people with scabies, 2 to 80 years of ageLocation: India, Pakistan
Oral ivermectin 200 μg/kg (1 to 3 doses) may leads to lower complete clearance ‐ week 1 compared with topical permethrin 5% cream (1 to 3 applications) (low certainty).
5 findings from 1 review
RR 0.65 [0.54, 0.78]
6 studies · 613 participants
Low
RR 0.91 [0.76, 1.08]
5 studies · 459 participants
Low
RR 1 [0.86, 1.16]
1 study · 80 participants
High
Show 2 more findings
Complete clearance · people with scabies, 5 to 60 years of ageLocation: Egypt, Pakistan
Oral ivermectin 200 μg/kg (1 to 2 doses) showed no clear difference in complete clearance ‐ week 1 ‐ IVER 1 dose versus PER on 5… compared with topical permethrin 5% lotion (1 to 5 applications) (low certainty).
4 findings from 1 review
RR 0.7 [0.47, 1.03]
1 study · 107 participants
Low
RR 1 [0.78, 1.29]
1 study · 120 participants
Low
RR 0.97 [0.81, 1.17]
1 study · 107 participants
Moderate
Show 1 more finding
Number of participants with ≥ 1 AE ‐ week 2 ‐ IVER 2 doses versus PER on 5 consecutive nights · people with scabies, 5 to 60 years of ageLocation: Egypt, Pakistan
It is very uncertain whether oral ivermectin 200 μg/kg (1 to 2 doses) changes number of participants with ≥ 1 AE ‐ week 2 ‐ IVER 2 doses versus… compared with topical permethrin 5% lotion (1 to 5 applications) (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with scabies, 5 to 60 years of ageLocation: Egypt, Pakistan
1 finding from 1 review
Complete clearance · people with scabies, 5 to 80 years of ageLocation: Egypt, India
Oral ivermectin 200 μg/kg (1 to 3 doses) showed no clear difference in complete clearance ‐ week 1 compared with topical ivermectin 1% lotion/solution (1 to 3 applications) (low certainty).
3 findings from 1 review
RR 0.84 [0.65, 1.08]
1 study · 62 participants
Low
RR 1 [0.94, 1.06]
1 study · 62 participants
Moderate
RR 0.99 [0.95, 1.03]
2 studies · 272 participants
Moderate
Number of participants with ≥ 1 AE ‐ week 4 · people with scabies, 5 to 80 years of ageLocation: Egypt, India
It is very uncertain whether oral ivermectin 200 μg/kg (1 to 3 doses) changes number of participants with ≥ 1 AE ‐ week 4 compared with topical ivermectin 1% lotion/solution (1 to 3 applications) (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with scabies, 5 to 80 years of ageLocation: Egypt, India
1 finding from 1 review
Number of participants with ≥ 1 AE ‐ week 2 · people with scabies, 2 to 80 years of ageLocation: India, Pakistan
1 finding from 1 review
Number of participants with ≥ 1 AE ‐ week 4 · people with scabies, 2 to 80 years of ageLocation: India, Pakistan
Oral ivermectin 200 μg/kg (1 to 3 doses) showed no clear difference in number of participants with ≥ 1 AE ‐ week 4 compared with topical permethrin 5% cream (1 to 3 applications) (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with scabies, 2 to 80 years of ageLocation: India, Pakistan
1 finding from 1 review
Uterine fibroid‐related symptoms (duration of uterine bleeding, measured at 12 weeks; lower = better) · women with uterine fibroids
1 finding from 1 review
Uterine fibroid‐related symptoms (abnormal uterine bleeding, measured at 12 weeks, with the pictorial blood assessment chart (PBAC); lower = better) · women with uterine fibroids
1 finding from 1 review
Fibroid size · women with uterine fibroids
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (hot flushes) · women with uterine fibroids
1 finding from 1 review
Primary: investigator‐rated good/excellent control of symptoms · people with hand eczema, continuously for 6 months, significant disability, inadequate response to conventional treatment, confirmation by…
Oral immunosuppressants: oral cyclosporin showed no clear difference in primary: investigator‐ rated good/excellent control of symptomsb compared with topical betamethasone dipropionate (moderate certainty).
1 finding from 1 review
Primary: participant‐rated good/excellent control of symptoms · people with hand eczema, continuously for 6 months, significant disability, inadequate response to conventional treatment, confirmation by…
Oral immunosuppressants: oral cyclosporin showed no clear difference in primary: participant‐rated good/excellent control of symptomsb compared with topical betamethasone dipropionate (moderate certainty).
1 finding from 1 review
Number of participants with any adverse event (primary tolerability outcome) · people with hand eczema, continuously for 6 months, significant disability, inadequate response to conventional treatment, confirmation by…
Oral immunosuppressants: oral cyclosporin showed no clear difference in primary: adverse events ‐ at least 1 adverse event compared with topical betamethasone dipropionate (moderate certainty).
1 finding from 1 review
Secondary: investigator‐rated reduction in severity ‐ DASIb · people with hand eczema, continuously for 6 months, significant disability, inadequate response to conventional treatment, confirmation by…
1 finding from 1 review
Change in disability score · non‐ambulatory children with SMA types II and III
1 finding from 1 review
Muscle strength · non‐ambulatory children with SMA types II and III
1 finding from 1 review